Cartesian Therapeutics, Inc. (RNAC)
(Delayed Data from NSDQ)
$23.32 USD
-3.97 (-14.55%)
Updated Jun 17, 2024 04:00 PM ET
After-Market: $23.34 +0.02 (0.09%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth A Momentum D VGM
Price, Consensus and EPS Surprise
RNAC 23.32 -3.97(-14.55%)
Will RNAC be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for RNAC based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for RNAC
Cartesian (RNAC) Up as FDA Grants RMAT Tag to Descartes-08
What Makes Cartesian Therapeutics, Inc. (RNAC) a New Buy Stock
RNAC: What are Zacks experts saying now?
Zacks Private Portfolio Services
Wall Street Analysts Think Cartesian Therapeutics, Inc. (RNAC) Could Surge 141%: Read This Before Placing a Bet
Wall Street Analysts Believe Cartesian Therapeutics, Inc. (RNAC) Could Rally 146.24%: Here's is How to Trade
Down -30.75% in 4 Weeks, Here's Why You Should You Buy the Dip in Cartesian Therapeutics, Inc. (RNAC)
Other News for RNAC
Cartesian Therapeutics’ Strategic Governance and Incentive Enhancements
Analysts Offer Insights on Healthcare Companies: Cartesian Therapeutics (RNAC), Encompass Health (EHC) and Sarepta Therapeutics (SRPT)
After Kyverna data, Oppenheimer says Cartesian 'can exploit' CAR-T's 'baggage'
Cartesian Therapeutics Announces New Employment Inducement Grant
Cartesian Therapeutics announces employee inducement grant